Interstitial Lung Disease Clinical Trial Pipeline Insights | DelveInsight

Interstitial lung disease Pipeline involves 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, as per DelveInsight

New Delhi, INDIA


Las Vegas, USA, June 22, 2022 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Clinical Trial Pipeline Insights | DelveInsight

Interstitial lung disease Pipeline involves 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, as per DelveInsight

DelveInsight’s 'Interstitial Lung Disease Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline interstitial lung disease therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the interstitial lung disease pipeline domain.

Key Takeaways from the Interstitial Lung Disease Pipeline Report

  • DelveInsight’s interstitial lung disease Pipeline report depicts a robust space with 120+ active players working to develop 120 + pipeline therapies for interstitial lung disease treatment. 
  • The leading interstitial lung disease companies such as AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, others are developing novel drug candidates to improve the interstitial lung disease treatment landscape.
  • Key interstitial lung disease pipeline therapies in various stages of development include AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280,  Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
  • In March 2022, Blade Therapeutics, announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. Cudetaxestat (BLD-0409), a non-competitive, reversible inhibitor of autotaxin, has demonstrated direct anti-fibrotic activity and differentiating preclinical and biochemical characteristics which support the potential for a treatment profile in lung and liver fibrosis. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis.
  • In February 2022, Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs)
  • In February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers
  • In January 2022, Horizon Therapeutics announced the first patient has enrolled in a Phase IIb pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with IPF, the most common interstitial lung disease. HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. LPAR1 signaling has been implicated in fibrosis and inflammation, and preclinical and clinical evidence support the antifibrotic potential of LPAR1 antagonism across multiple organ systems, including both lung and skin.
  • In November 2021, Biotech Acquisition Company and Blade Therapeutics, Inc. entered into a definitive merger agreement. Upon the closing of the transaction, which is anticipated to occur in the first quarter of 2022, the combined company will be renamed Blade Biotherapeutics, Inc
  • In October 2021, Agomab Therapeutics announced that it entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders. 
  • In July 2021, FibroGen announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF)
  • In February 2021, ImmunoMet Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for IM156, an investigational Protein Complex 1 inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF) as well as granting it Orphan Drug Designation.

Request a sample and discover the recent breakthroughs and advances in interstitial lung disease drug treatment @ Interstitial Lung Disease Pipeline Outlook

The interstitial lung disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage interstitial lung disease products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the interstitial lung disease pipeline landscape.

Interstitial Lung Disease Overview

Interstitial lung disease is a chronic (long-term) lung condition. It occurs as a result of injury between the air sacs in the lung. The scarring of the lung creates breathing difficulties. Interstitial lung disease causes breathlessness and a dry cough during exercise. These problems may worsen gradually or rapidly. The cause of interstitial lung disease is unknown; however, inhaling environmental or occupational pollutants such as inorganic or organic dust is thought to be a major contributing factor.

The primary interstitial lung disease symptoms are dry cough and shortness of breath at rest or aggravated by exertion. The interstitial lung disease diagnosis tests include- Chest X-ray, Lung function test, CT scan, and lung biopsy. 

Find out more about interstitial lung disease treatment @ Interstitial Lung Disease Treatment Guidelines

A snapshot of the interstitial lung disease Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
RO-0220912 Roche Pre-registration Collagen inhibitors; Cytokine inhibitors Oral
ATYR1923 aTyr Pharma Phase III Neuropilin-2 modulators Intravenous
BI 1015550 Boehringer Ingelheim Phase III Type 4 cyclic nucleotide phosphodiesterase inhibitors Oral
Pamrevlumab FibroGen Phase III Connective tissue growth factor inhibitors Intravenous
Zinpentraxin alfa Roche Phase III Transforming growth factor beta1 modulator Intravenous
LT 0011 LTT Bio-Pharma Phase II Antioxidants Intravenous
Abatacept Bristol-Myers Squibb Phase II T cell activation inhibitors Intravenous
PRA023 Prometheus Biosciences Phase II Tumour necrosis factor ligand superfamily member 15 inhibitors Intravenous
Yifenidone  HEC Pharm Phase II NA Oral
 Riociguat Bayer Phase II Guanylate cyclase stimulants Oral
Treprostinil Palmitil Insmed Phase II Epoprostenol receptor agonist Inhalation
BMS 986278 Bristol-Myers Squibb Phase II Lysophosphatidic acid receptor antagonist Oral
Pirfenidone inhalation Avalyn Pharma  Phase II Collagen inhibitor; Cytokine inhibitor Inhalation
Deupirfenidone PureTech Health Phase II Collagen inhibitor; Cytokine inhibitor Oral
Ianalumab Novartis

 
Phase II Antibody-dependent cell cytotoxicity Subcutaneous
HZN-825 Horizon  Phase II Lysophosphatidic acid receptor antagonist Oral
Tipelukast MediciNova Phase II 5-lipoxygenase inhibitor Oral
ENV-101 Endeavor BioMedicines Phase II SMO protein inhibitors Oral
PLN-74809 Pliant Therapeutics Phase II Integrin alphavbeta1 inhibitor Oral
KD025 Kadmon Pharmaceuticals Phase II Rho-associated kinase inhibitor Oral
Setanaxib  GenKyoTex Phase II NOX1 protein inhibitor Oral
LTI-03 Lung Therapeutics  Phase I Caveolin-1 replacements Inhalation
AD-214 AdAlta Phase I CXCR4 receptor antagonists Intravenous
AK 3280 Ark Biosciences Phase I NA Oral

Learn more about the novel and emerging interstitial lung disease therapies @ Interstitial Lung Disease Clinical Trials

Interstitial lung disease Therapeutics Assessment

The Interstitial Lung Disease Pipeline report proffers an integral view of the interstitial lung disease emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the interstitial lung disease Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical
  • Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
  • Therapeutics Assessment By Mechanism of Action: CXCR4 receptor antagonists, T cell activation inhibitors, Neuropilin-2 modulator, Collagen inhibitor, Cytokine inhibitor, Antioxidants, Caveolin-1 replacements, Rho-associated kinase inhibitor, Integrin alphavbeta1 inhibitors, NOX1 protein inhibitor, SMO protein inhibitor, 5-lipoxygenase inhibitor, Antibody-dependent cell cytotoxicity, Transforming growth factor beta1 modulator, Lysophosphatidic acid receptor antagonist and Epoprostenol receptor agonist, others
  • Key interstitial lung disease Companies: AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Blade Therapeutics, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, others
  • Key interstitial lung disease Pipeline Therapies: AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Cudetaxestat, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.

Dive deep into rich insights into new interstitial lung disease drugs, visit @ Drugs for Interstitial Lung Disease Treatment 

Table of Contents

1. Introduction
2. Executive Summary
3. Interstitial Lung Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Interstitial Lung Disease Pipeline Therapeutics
6. Interstitial Lung Disease Pipeline: Late Stage Products (Phase III)
6.1 ATYR1923: aTyr Pharma
7. Interstitial Lung Disease Pipeline: Mid Stage Products (Phase II)
7.1 KD025: Kadmon Pharmaceuticals
8. Interstitial Lung Disease Pipeline: Early Stage Products (Phase I)
8.1 LTI-03: Lung Therapeutics
9. Interstitial Lung Disease Pipeline: Preclinical Stage Products
9.1 PRS-220: Pieris Pharmaceuticals 
10. Interstitial Lung Disease Pipeline Therapeutics Assessment
11. Inactive Products in the Interstitial Lung Disease Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies in the Interstitial Lung Disease Pipeline
14. Key Products in the Interstitial Lung Disease Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the interstitial lung disease pipeline therapeutics, reach out @ Interstitial Lung Disease Medications

Related Reports

Interstitial Lung Disease Epidemiology Forecast

Interstitial Lung Disease Epidemiology Forecast–2032 report delivers an in-depth understanding of the interstitial lung disease, historical and forecasted epidemiology as well as the interstitial lung disease epidemiology trends.

Interstitial Lung Disease Market

Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key interstitial lung disease companies including AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, among others.

Systemic Sclerosis associated Interstitial Lung Disease Pipeline


Systemic Sclerosis associated Interstitial Lung Disease Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape including clinical and non-clinical stage products, and the key systemic sclerosis-associated interstitial lung disease companies including Beijing Continent Pharmaceutical Co, Ltd., Shanghai Genomics, Inc., GNI-EPS Pharmaceuticals, Inc., among others.

Systemic Sclerosis associated Interstitial Lung Disease Market

Systemic Sclerosis associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key systemic sclerosis associated interstitial lung disease companies including Beijing Continent Pharmaceutical Co, Ltd., Shanghai Genomics, Inc., GNI-EPS Pharmaceuticals, Inc., among others.

Progressive Fibrosing Interstitial Lung Disease Pipeline

Progressive Fibrosing Interstitial Lung Disease Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape including clinical and non-clinical stage products, and the key progressive fibrosing interstitial lung disease companies including Sunshine Lake Pharma Co., Ltd., Boehringer Ingelheim, Hoffmann-La Roche, among others.

Progressive Fibrosing Interstitial Lung Disease Market

Progressive Fibrosing Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key progressive fibrosing interstitial lung disease companies including Sunshine Lake Pharma Co., Ltd., Boehringer Ingelheim, Hoffmann-La Roche, among others.


Other Trending Reports

Pediatric Growth Hormone Deficiency Market | Non-Cystic Fibrosis Bronchiectasis Market | X-Linked Retinitis Pigmentosa Market | Otitis Media Market | Central Retinal Vein Occlusion Market | Frontotemporal Dementia Market | Follicular Lymphoma Market | Diabetes Market | Blastic Plasmacytoid Dendritic Cell Neoplasm Market | Bevacizumab Biosimilars Insight | Bacterial Conjunctivitis Market | FENEBRUTINIB Market | Peripherally Inserted Central Catheter Devices Market | Cardiac Biomarkers Testing Devices Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 

 

Contact Data